BR112020016373A2 - Composição imunogênica compreendendo antígenos de estafilococos - Google Patents
Composição imunogênica compreendendo antígenos de estafilococos Download PDFInfo
- Publication number
- BR112020016373A2 BR112020016373A2 BR112020016373-2A BR112020016373A BR112020016373A2 BR 112020016373 A2 BR112020016373 A2 BR 112020016373A2 BR 112020016373 A BR112020016373 A BR 112020016373A BR 112020016373 A2 BR112020016373 A2 BR 112020016373A2
- Authority
- BR
- Brazil
- Prior art keywords
- seq
- amino acid
- immunogenic composition
- antigen
- fact
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1802339.0A GB201802339D0 (en) | 2018-02-13 | 2018-02-13 | Immunogenic composition |
| GB1802339.0 | 2018-02-13 | ||
| PCT/EP2019/053463 WO2019158537A1 (en) | 2018-02-13 | 2019-02-12 | Immunogenic composition comprising staphylococcal antigens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112020016373A2 true BR112020016373A2 (pt) | 2020-12-15 |
Family
ID=61731342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112020016373-2A BR112020016373A2 (pt) | 2018-02-13 | 2019-02-12 | Composição imunogênica compreendendo antígenos de estafilococos |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11426455B2 (https=) |
| EP (1) | EP3752183A1 (https=) |
| JP (1) | JP2021514387A (https=) |
| KR (1) | KR20200121825A (https=) |
| CN (1) | CN112153980A (https=) |
| AR (1) | AR114627A1 (https=) |
| AU (1) | AU2019221496B2 (https=) |
| BR (1) | BR112020016373A2 (https=) |
| CA (1) | CA3090609A1 (https=) |
| EA (1) | EA202091690A1 (https=) |
| GB (1) | GB201802339D0 (https=) |
| IL (1) | IL276661B2 (https=) |
| MX (1) | MX2020008454A (https=) |
| SG (1) | SG11202007676RA (https=) |
| WO (1) | WO2019158537A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201721582D0 (en) * | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | S aureus antigens and immunogenic compositions |
| CN110511950B (zh) * | 2019-07-29 | 2022-03-08 | 因之彩生物科技（武汉）有限公司 | Pab蛋白在构建具有类伴侣样蛋白作用的融合蛋白表达载体中的应用 |
| EP3777884A1 (en) * | 2019-08-15 | 2021-02-17 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
| WO2021122551A1 (en) | 2019-12-19 | 2021-06-24 | Glaxosmithkline Biologicals Sa | S. aureus antigens and compositions thereof |
| MY207887A (en) * | 2020-05-01 | 2025-03-26 | Sinocelltech Ltd | Method for improving immunogenicity of protein/peptide antigen |
| JP7423133B2 (ja) | 2020-09-21 | 2024-01-29 | エルジー エナジー ソリューション リミテッド | リチウム二次電池の活性化方法及びリチウム二次電池 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ553776A (en) * | 2004-09-22 | 2010-05-28 | Glaxosmithkline Biolog Sa | Immunogenic composition comprising staphylococcal PNAG and Type 5 and/or 8 Capsular polysaccharide or oligosaccharide. |
| GB0526038D0 (en) | 2005-12-21 | 2006-02-01 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| SG188102A1 (en) * | 2008-01-31 | 2013-03-28 | Trinity College Dublin | Treatment of microbial infections |
| AU2015202532A1 (en) | 2009-04-14 | 2015-06-04 | Novartis Ag | Compositions for immunising against Staphylococcus aureus |
| SA110310528B1 (ar) * | 2009-06-22 | 2014-07-02 | Wyeth Llc | التركيبات المولدة للمناعة لأنتيجينات ستافيلوكوكس أوريس |
| US20140037650A1 (en) | 2009-07-24 | 2014-02-06 | University Of Chicago | Compositions and methods related to antibodies to staphylococcal proteins isda or isdb |
| EP3281639B1 (en) * | 2010-05-06 | 2020-11-11 | GlaxoSmithKline Biologicals S.A. | Capsular gram-positive bacteria bioconjugate vaccines |
| CA2803298C (en) * | 2010-07-02 | 2020-07-14 | The University Of Chicago | Compositions and methods related to protein a (spa) variants |
| EP2614074A1 (en) | 2010-09-09 | 2013-07-17 | The University of Chicago | Methods and compositions involving protective staphylococcal antigens |
| EP2654784B1 (en) | 2010-12-22 | 2016-12-07 | Wyeth LLC | Stable immunogenic compositions of staphylococcus aureus antigens |
| BR112014003315A2 (pt) * | 2011-08-15 | 2017-03-01 | Univ Chicago | composições e métodos relacionados a anticorpos para a proteína a estafilocócica |
| US20150202277A1 (en) * | 2012-08-31 | 2015-07-23 | Novartis Ag | Stabilised proteins for immunising against staphylococcus aureus |
| US10195262B2 (en) | 2013-12-04 | 2019-02-05 | Glaxosmithkline Biologicals S.A. | Prevention of Staphylococcus aureus infections by glycoprotein vaccines synthesized in Escherichia coli |
| CN106103469B (zh) * | 2014-03-26 | 2020-11-27 | 葛兰素史密丝克莱恩生物有限公司 | 突变型葡萄球菌抗原 |
| GB201721576D0 (en) * | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | Hla antigens and glycoconjugates thereof |
| GB201721582D0 (en) * | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | S aureus antigens and immunogenic compositions |
-
2018
- 2018-02-13 GB GBGB1802339.0A patent/GB201802339D0/en not_active Ceased
-
2019
- 2019-02-12 JP JP2020565545A patent/JP2021514387A/ja active Pending
- 2019-02-12 SG SG11202007676RA patent/SG11202007676RA/en unknown
- 2019-02-12 WO PCT/EP2019/053463 patent/WO2019158537A1/en not_active Ceased
- 2019-02-12 CN CN201980025676.7A patent/CN112153980A/zh active Pending
- 2019-02-12 EP EP19706423.1A patent/EP3752183A1/en not_active Withdrawn
- 2019-02-12 BR BR112020016373-2A patent/BR112020016373A2/pt not_active IP Right Cessation
- 2019-02-12 MX MX2020008454A patent/MX2020008454A/es unknown
- 2019-02-12 CA CA3090609A patent/CA3090609A1/en active Pending
- 2019-02-12 KR KR1020207025858A patent/KR20200121825A/ko not_active Withdrawn
- 2019-02-12 IL IL276661A patent/IL276661B2/en unknown
- 2019-02-12 AR ARP190100345A patent/AR114627A1/es not_active Application Discontinuation
- 2019-02-12 US US16/968,895 patent/US11426455B2/en active Active
- 2019-02-12 EA EA202091690A patent/EA202091690A1/ru unknown
- 2019-02-12 AU AU2019221496A patent/AU2019221496B2/en not_active Ceased
-
2022
- 2022-07-20 US US17/869,055 patent/US20230052495A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US11426455B2 (en) | 2022-08-30 |
| EA202091690A1 (ru) | 2020-11-27 |
| US20230052495A1 (en) | 2023-02-16 |
| WO2019158537A1 (en) | 2019-08-22 |
| CN112153980A (zh) | 2020-12-29 |
| KR20200121825A (ko) | 2020-10-26 |
| IL276661B2 (en) | 2023-08-01 |
| EP3752183A1 (en) | 2020-12-23 |
| US20210023192A1 (en) | 2021-01-28 |
| MX2020008454A (es) | 2021-03-25 |
| AR114627A1 (es) | 2020-09-30 |
| CA3090609A1 (en) | 2019-08-22 |
| AU2019221496B2 (en) | 2022-12-08 |
| AU2019221496A1 (en) | 2020-08-27 |
| GB201802339D0 (en) | 2018-03-28 |
| IL276661A (en) | 2020-09-30 |
| IL276661B1 (en) | 2023-04-01 |
| SG11202007676RA (en) | 2020-09-29 |
| JP2021514387A (ja) | 2021-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230052495A1 (en) | Immunogenic composition comprising staphylococcal antigens | |
| KR101748453B1 (ko) | 폐렴구균(Ｓｔｒｅｐｔｏｃｏｃｃｕｓ Ｐｎｅｕｍｏｎｉａｅ)에 대항하는 백신과 조성물 | |
| ES2688883T3 (es) | Fragmentos mutantes de OspA y métodos y usos relacionados con los mismos | |
| KR20120034612A (ko) | 황색 포도상구균에 대한 면역화를 위한 조성물 | |
| JP2007515180A (ja) | ワクチン | |
| CN106103469B (zh) | 突变型葡萄球菌抗原 | |
| US11819544B2 (en) | Immunogenic composition | |
| JP2024540918A (ja) | リポ多糖（ｌｐｓ）欠損アシネトバクター・バウマニ多価ワクチン | |
| CN102488898B (zh) | 龋齿疫苗及制备方法 | |
| US20220395566A1 (en) | Immunogenic composition | |
| JP2024517754A (ja) | Ｏ－結合型グリコシル化に十分な最小シークオン | |
| US12472249B2 (en) | Glyconjugate vaccines | |
| HK40047921A (en) | Mutant staphylococcal antigens | |
| TW201726164A (zh) | 脂質體疫苗 | |
| HK1207982B (en) | Mutant fragments of ospa and methods and uses relating thereto | |
| HK1172254A (en) | Vaccines and compositions against streptococcus pneumoniae |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2866 DE 09/12/2025. |